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E-mail address: hr@zellkult.techfak.uni-bielefeld.dAngiotensinogen is well known as source protein for a group of potent vasoactive hormones, how-
ever, a discrete biochemical activity of the angiotensinogen body is not known. Here we investigated
angiotensinogen from the lamprey Lampetra ﬂuviatilis (L. ﬂuviatilis), an early-diverged vertebrate.
The recombinantly produced protein showed progressive inhibitory activity towards human a-
thrombin with a second-order rate constant of 2.6  104 M1 min1. Heparin enhanced the reaction
rate >800-fold with a bell-shaped dose-response curve and a stoichiometry of inhibition (SI) of 1.3,
revealing lamprey angiotensinogen as an effective a-thrombin inhibitor. Genomic, biochemical, and
protein sequence data indicate that angiotensinogen and heparin cofactor II (HCII) originated from a
common ancestral thrombin antagonist, thus providing insight into an early stage of thrombin
control.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Protease-inhibiting serpins act through a suicide mechanismIn humans and other vertebrates, processing of angiotensinogen
results in the release of the angiotensins, a group of hormones
exhibiting vasoconstrictor activity and multiple other functions,
including osmoregulation [1,2]. Following secretion, angiotensino-
gen is cleaved by renin that liberates the N-terminal decapeptide
angiotensin I (Ang I) (Fig. 1A), a step modulated by a redox switch
[3]. Ang I processing by the dipeptidyl peptidase angiotensin-
converting enzyme 1 (ACE1) generates Ang II, the major effector
peptide, but alternative routes of Ang II production are also known
[1]. Due to its linkage with hypertension, the angiotensinogen
locus has received vast attention [4].
Almost three decades ago, angiotensinogen was recognised as a
member of the serpin (serine protease inhibitor) superfamily [5].
Serpins are a class of structurally related proteins that mostly exe-
cute antiproteolytic functions by forming complexes with their tar-
get enzymes. Thrombin, for example, is kept in check by two serpins,
antithrombin (AT) and HCII that act in different physiological con-
texts [6]. In the presence of heparin, AT rapidly inactivates thrombin
and other coagulation proteases, thus curbing procoagulant activity.
HCII is a speciﬁc thrombin inhibitor that requires glycosaminogly-
cans (GAGs), suchasdermatan sulfate (DS) orheparin for full activity
[7]. These cofactorsmay elicit exosite contacts that enhance enzyme
inhibition [8,9]. Current evidence supports a role for HCII in modu-
lating the response to vascular injury and/or to inﬂammatory
damage of blood vessels [10,11].chemical Societies. Published by E
e (H. Ragg).that depends on their mobile reactive site loop (RSL), which is
presented to the enzyme. After docking, conformational changes
result in formation of stable enzyme/inhibitor complexes. Non-
inhibitory serpins do not undergo these rearrangements, often due
to bulky RSL residues [12]. Prominent examples of non-inhibitory
serpins are the mammalian angiotensinogens and some hormone
transporters, such as thyroxin binding globulin or corticoid binding
globulin [12]. In human angiotensinogen, the imino acid proline
at P10 and the large glutamate at P8 (Fig. 1B) have been proposed
to prevent the structural changes required for the inhibitory
function [13].
We have recently isolated cDNA and gene sequences coding
for angiotensinogen from L. ﬂuviatilis [14]. Three lines of evi-
dence corroborate that the cloned lamprey sequences are orthol-
ogous to angiotensinogen: (i) The lamprey protein, clearly a
serpin [14], contains an N-terminal decapeptide sequence with
60% identity to human angiotensin I (Fig. 1A). (ii) Vertebrate ser-
pins have been classiﬁed into six groups (V1–V6) based on the
exon-intron organisations of their genes. Number and positions
of introns vary strongly between the different groups, but are
highly conserved within each group, apparently reﬂecting com-
mon ancestry of genes sharing an equivalent organisation. HCII
(including the lamprey ortholog) and angiotensinogen are both
members of group V2 that exhibit three characteristic introns
[14,15]. (iii) A tridecapeptide including the cyclostome angioten-
sin sequence elicits a vasoresponse in lampreys [16]. Since these
animals possess a simple coagulation system that exhibits major
procoagulant factors [17,18], lampreys are thought to reﬂect an
early phase of vertebrate coagulation.lsevier B.V. All rights reserved.
Fig. 1. Important functional elements of angiotensinogen and HCII. (A) Angiotensin
sequences. The systematic species names and GenBank accession numbers are
given in brackets. The sea lamprey sequences are from the Pre-Ensembl database
(http://pre.ensembl.org/Petromyzon_marinus/Info/Index; angiotensinogen: Con-
tig1818; HCII: Contig1544). (B) RSL sequences of angiotensinogen, HCII, and AT.
The nomenclature of Schechter and Berger [28] is used to identify the residues
adjacent to the N- or C-terminal side of the scissile bond, with P1 and P10 directly
ﬂanking the cleavage site. (C) Sequence alignment of the helix D regions of
thrombin inhibiting serpins. Basic amino acids (Arg, Lys) are reproduced in color.
Human a1-antitrypsin (A1AT) is included as reference serpin. The size of helix D
may vary dependent on the physiological state of the individual serpins.
Fig. 2. Heparin afﬁnity chromatography of hLA. Medium of hLA-expressing COS-7
cells was adjusted to pH 7.4 and applied to a Heparin HP column. Bound material
was eluted by a stepwise increase of the NaCl concentration (100–3000 mM, as
indicated on top). Fractions were blotted and analysed with anti-angiotensin
antibodies. F, column ﬂow-through; W, combined washing fractions.
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harbor an inhibitory RSL [14]. Here we have characterised this mol-
ecule, revealing unexpected insight into the evolution of blood
coagulation control.
2. Materials and methods
2.1. Materials
Goat antibodies detecting human angiotensins I–III (Angioten-
sin N-10, sc-7419) were from Santa Cruz Biotechnology. Human
a-thrombin (>3400 NIH units/mg), anti-hemagglutinin antiserum
(H6908), DS and heparin (140 USP units/mg) from porcine intesti-
nal mucosa were purchased from Sigma. Chromozym TH was from
Roche. Heparin HP and Q Sepharose Fast Flow were from GE
Healthcare.
2.2. Expression of lamprey angiotensinogen
The genuine angiotensin sequence was converted into the hu-
man homologue by incubating the vector pcDNA3.1 harbouring L.
ﬂuviatilis angiotensinogen cDNA with Pfu DNA polymerase in the
presence of two complementary mutagenic primers (50-CTACGAC-
GAtCGGgtCTACATcCAcCCCTTCC and 50-GGAAGGGgTGgATGTAGac
CCGaTCGTCGTAG; mismatches to the template are in lowercase
letters). After 18 PCR cycles (30 s at 95 C, 1 min at 50 C, 14 min
at 68 C), the DNA was digested with DpnI, transformed into
E. coli, and analysed by sequencing. The modiﬁed angiotensinogen,
referred to as hLA (humanised lamprey angiotensinogen), wasexpressed in COS-7 cells, using poly(ethyleneimine) for transfec-
tion [19]. Expression in HEK293-EBNA cells was performed with
a vector carrying a hygromycin resistance gene. After 3–4 weeks
of selection with hygromycin (250 lg/ml), clones were picked, ex-
panded and assayed for angiotensinogen production. Western blot
analysis was done as described [20] with non-fat dry milk as block-
ing agent. Detection was accomplished with anti-angiotensin anti-
bodies and peroxidase-linked mouse anti-goat IgGs.
2.3. Heparin afﬁnity chromatography and puriﬁcation of lamprey
angiotensinogen
Serum-free medium of hLA-expressing COS-7 cells (40 ml) was
adjusted to 10 mM sodium phosphate, pH 7.4 and applied to a
Heparin HP column (1 ml) equilibrated with the same buffer. After
washing, hLA was eluted by increasing the NaCl concentration in
100 mM steps. Fractions were subjected to SDS–PAGE and ana-
lysed by Western blotting.
hLA was puriﬁed by adjusting medium (400 ml) of transfected
HEK293-EBNA cells to 25 mM sodium phosphate, 20 mM NaCl,
pH 6.4 (buffer A), 0.1% (v/v) PMSF, followed by chromatography
on Q Sepharose Fast Flow, using buffer A. The ﬂow-through was
adjusted to 100 mM Tris–citrate, 225 mM NaCl (pH 7.4) and ap-
plied to a 5 ml heparin-Sepharose column. Following washing at
0.35 M NaCl, the 0.8 M NaCl fraction was concentrated and frozen
until use.
2.4. Complex formation and inhibition kinetics
Enzyme/inhibitor complexes were generated by incubating hu-
man a-thrombin (0.3 NIH units) with the supernatant from trans-
fected COS-7 cells at 25 C in the absence or presence of GAGs.
After addition of Laemmli sample buffer, the reactions were ana-
lysed byWestern blotting. Second-order rate constants were deter-
mined at 25 C by monitoring Chromozym TH cleavage at 405 nm
as described, using a 10-fold molar excess of inhibitor (50 nM, as
determined with the Bradford assay) [21]. DS was treated with so-
dium nitrite and dialysed before use. SI values were determined as
described [21].
3. Results
3.1. Lamprey angiotensinogen binds to heparin
In order to enable detection of lamprey angiotensinogen
with anti-human angiotensin antibodies, the genuine angiotensin
II sequence was switched into the human equivalent
(26ERPYMQPF35? DRVYIHPF, numbering refers to unprocessed
angiotensinogen). Expression of the variant (478 residues,
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cells resulted in secretion of a 65 kDa protein as detected in Wes-
tern blots with an anti-angiotensin antiserum (Figs. 2 and 3). An
additional minor band (59 kDa) is probably due to differential
glycosylation (potential N-glycosylation sites: 149NGS and 293NSS,
respectively). No such signals were observed with the empty vec-
tor, excluding that endogenous angiotensinogen caused the im-
mune reaction (not shown). Since lamprey angiotensinogen
depicts two clusters of basic residues (91KRGRKDKKKSKTQR104,
169KKKAKSMKYFARLNGALYKR188) resembling heparin binding mo-
tifs, we explored, whether hLA interacts with heparin. Fig. 2 shows
that hLA requires 600–700 mM NaCl for elution from heparin–
Sepharose.
3.2. Complex formation with thrombin
The distinct heparin afﬁnity of lamprey angiotensinogen and its
RSL sequence caused us to suspect thrombin as a target. Recombi-
nant hLA from COS-7 cells was therefore incubated with human a-
thrombin (36.5 kDa). Formation of thrombin/hLA complexes was
observed after protracted incubation periods, indicating that hLA
has progressive thrombin inhibitory activity (Fig. 3A). Addition of
heparin resulted in drastically accelerated complex formationFig. 3. Lamprey angiotensinogen forms complexes with a-thrombin. Medium
(20 lL) of hLA expressing COS-7 cells was incubated with human a-thrombin (0.3
NIH units) for the times indicated and analysed by Western blotting. (A) Complex
formation in the absence, or (B) presence of 50 U/ml heparin, or (C) 400 lg/ml DS.
(D) Complex formation (incubation periods in brackets) of native lamprey angio-
tensinogen containing an N-terminal hemagglutinin tag (HA-tag-LA) with human
a-thrombin in the absence of GAGs (30 min), presence of 400 lg/ml DS (20 min) or
50 U/ml heparin (2 min); lane c: control. The positions of hLA, HA-tag-LA and
complexes (TC) are marked. For detection, antibodies directed against human
angiotensin (A–C) or against the hemagglutinin tag (D) were used.(Fig. 3B). High concentrations of DS also expedited enzyme/
inhibitor interaction, though less effectively (Fig. 3C). Control
experiments conﬁrmed that switching to the human angiotensin
sequence was not responsible for complex formation. Fig. 3D
shows that native lamprey angiotensinogen with a standard hem-
agglutinin-tag (YPYDVPDYA) at the N-terminus also can form com-
plexes with human a-thrombin, as detected with anti-
hemagglutinin antibodies.
3.3. Kinetic parameters of enzyme/inhibitor interaction
To investigate the antiproteolytic activity of the lamprey serpin
further, HEK293-EBNA cell clones expressing hLA were established
and found to differ considerably in their capacity to produce the
inhibitor. With untransfected cells, a weak signal at 66 kDa was
visible in Western blots, possibly due to endogenous angiotensin-
ogen or due to cross-reaction with residual albumin from the ini-
tial production phase. The recombinant protein was puriﬁed by
anion exchange and heparin afﬁnity chromatography from the
medium of clone K4, one of the high-producer cell lines, resulting
in highly enriched hLA. Staining with PageBlue revealed two pro-
teins of 65 and 59 kDa in size on SDS–PAGE gels (not shown).
These proteins presumably represent glycosylation variants, since
each of them reacted with anti-angiotensin antibodies.
The puriﬁed material was used to determine the kinetic param-
eters of interaction with human a-thrombin. In the absence of
GAGs, the second order rate constant (k2) was
2.6  104 M1 min1. Heparin at 10 U/ml increased k2 about 810-
fold. The bell-shaped dose-response curve (Fig. 4) is consistent
with a template function for heparin, analogous to that implied
for the AT/thrombin/heparin interaction. DS accelerated inhibition
of human a-thrombin maximally 8.5-fold with a different dose-
response curve, indicating mechanistic differences to the
heparin-catalysed reaction. Lamprey angiotensinogen is an effective
inhibitor of human a-thrombin in the presence of 10 U/ml heparin,
as indicated by the SI value of 1.3. The inhibitory efﬁciency is
lower in the absence of cofactor (SI = 5.4) and in the presence of
1000 lg/ml DS (SI = 2.8).
4. Discussion
Our study reveals lamprey angiotensinogen as an inhibitory ser-
pin, in contrast to the human orthologue. Sequence alignments
indicate that, among vertebrates, only angiotensinogen of lam-
preys contains an RSL compatible with protease inhibition [14].
The maximal thrombin inhibition rate of lamprey angiotensinogen
(2.1  107 M1 min1 at 10 U/ml heparin) is lower than that re-
ported for DS activated human HCII (108 M1 min1) [21,22],Fig. 4. Heparin and dermatan sulfate enhance hLA-mediated inhibition of human
a-thrombin. Second order rate constants were measured as described under
Materials and methods.
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protease can inﬂuence the reaction kinetics [23]. A comparison
with the RSL sequences of AT and HCII illuminates the basis of
the anti-thrombin activity of lamprey angiotensinogen (Fig. 1B).
The P1 residue of AT is Arg as in most substrates of thrombin. HCII
and lamprey angiotensinogen, in contrast, possess hydrophobic P1
residues, and overall, their RSL sequences are similar. As exempli-
ﬁed by other serpins, ‘‘unfavorable’’ P1 residues may outperform
substrate-like residues in terms of inhibitory efﬁciency [24].
Since haemostasis and blood pressure control of lampreys are
largely unexplored, the role of angiotensinogen in these animals
is still elusive. Many lampreys exhibit an anadromous lifestyle, of-
ten restricted to distinct developmental phases. Since thrombin is
activated under hypernatremic conditions [25], angiotensinogen
might protect lampreys against inappropriate blood clotting in sea-
water. Angiotensin release, in turn, may help to control water loss
and osmotic pressure at increased salinity [26]. Many lampreys at-
tack ﬁsh to suck blood, however, whether they use angiotensino-
gen to anticoagulate the victims and to boost their circulatory
pressure for enduring blood supply remains to be investigated.
Database mining did not reveal AT in Petromyzon marinus andFig. 5. Evolution of serpin-mediated thrombin inhibition. Duplication of an ancestral thr
thrombin activity of angiotensinogen was lost in gnathostomes, but has survived in lamp
in gnathostomes, thus replacing angiotensinogen. Whether angiotensin (rectangle) was
residues ﬂanking the scissile bond are represented in the single-letter code for amino aci
group V2 serpins are delineated. Exons (and introns) are not drawn to scale.Lethenteron japonicum (an arctic lamprey), and our efforts to
detect AT cDNA in L. ﬂuviatilis failed. Angiotensinogen and HCII
thus appear to be key elements of thrombin inhibition in lampreys.
Uncovering lamprey angiotensinogen as a thrombin inhibitor
solidiﬁes the classiﬁcation of angiotensinogen and HCII as group
V2 serpins as inferred from their gene structures [14]. Concor-
dances on the protein level, including long N-terminal extensions
(though of low similarity) protruding beyond the serpin core, and
the similar RSL sequences in lampreys corroborate the common
ancestry of these proteins. The basic helix D region of lamprey
angiotensinogen (Fig. 1C), supposedly involved in GAG binding,
may represent another hint of kinship with HCII. Phylogenetic
analyses [27] clearly argue against homoplasy.
Unveiling the anti-thrombin activity of lamprey angiotensino-
gen has important implications for understanding the evolution
of thrombin regulation (Fig. 5). Apparently, thrombin inhibition
was initiated through an ancestral group V2 serpin. Whether
angiotensin was an integral part of this ancestor requires further
investigation. The offsprings may have covered overlapping aspects
of thrombin control seemingly perpetuated in lampreys. Gnathost-
omes, in contrast, lost the inhibitory activity of angiotensinogen,ombin inhibitor gene resulted in generation of angiotensinogen and HCII. The anti-
reys. Seemingly absent in lampreys, AT takes a key position as regulator of thrombin
part of the ancestral inhibitor is uncertain. RSLs are reproduced as ovals and the
ds. In the ancestral thrombin inhibitor gene, only the standard introns present in all
Y. Wang, H. Ragg / FEBS Letters 585 (2011) 2395–2399 2399possibly due to changes of the physiological network within
which thrombin acts. The advent of the broad-spectrum inhibitor
AT, for example, could have favoured loss of angiotensinogen’s
anti-proteolytic activity. The alternative, generation, in the lamprey
lineage, of an inhibitory angiotensinogen holds little appeal, since
multiple changes are necessary for evolving a cofactor-regulated
thrombin antagonist.
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